Argenx (ARGX) said Friday that Japan's Ministry of Health, Labour and Welfare approved its Vyvdura injection as a treatment for adult patients with chronic inflammatory demyelinating polyneuropathy, a progressive and debilitating neuromuscular disorder of the peripheral nervous system.
The approval is based on the results of a study, which showed that 69% of patients treated with the drug demonstrated clinical improvements, including in mobility, function and strength.
The Japanese regulator approved Vyvdura for manufacturing and marketing in January. The drug was launched in April for the treatment of generalized myasthenia gravis.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。